These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23225424)

  • 1. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
    Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
    Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.
    Judde JG; Rebucci M; Vogt N; de Cremoux P; Livartowski A; Chapelier A; Tran-Perennou C; Boye K; Defrance R; Poupon MF; Bras-Gonçalves RA
    Int J Cancer; 2007 Apr; 120(7):1579-90. PubMed ID: 17205515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
    Yang SH; Lin HY; Chang VH; Chen CC; Liu YR; Wang J; Zhang K; Jiang X; Yen Y
    Oncotarget; 2015 Sep; 6(27):23857-73. PubMed ID: 26160843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
    Hidalgo M; Amador ML; Jimeno A; Mezzadra H; Patel P; Chan A; Nielsen ME; Maitra A; Altiok S
    Mol Cancer Ther; 2006 Jul; 5(7):1895-903. PubMed ID: 16891476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
    Matsumoto K; Nagahara T; Okano J; Murawaki Y
    Oncol Rep; 2008 Oct; 20(4):863-72. PubMed ID: 18813828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma.
    Ito Y; Yamada D; Kobayashi S; Sasaki K; Iwagami Y; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Cancer Lett; 2024 Jul; 595():216997. PubMed ID: 38801887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
    Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
    Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.
    Zhang L; Qi Y; Xing K; Qian S; Zhang P; Wu X
    Oncol Rep; 2018 Aug; 40(2):1046-1054. PubMed ID: 29917169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
    Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
    Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
    Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K
    Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.
    Zhu H; Cheng H; Ren Y; Liu ZG; Zhang YF; De Luo B
    Mol Biol Rep; 2012 Apr; 39(4):4971-9. PubMed ID: 22160570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway.
    Thongpon P; Intuyod K; Chomwong S; Pongking T; Klungsaeng S; Muisuk K; Charoenram N; Sitthirach C; Thanan R; Pinlaor P; Pinlaor S
    Sci Rep; 2024 Jul; 14(1):16059. PubMed ID: 38992159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
    Okita R; Wolf D; Yasuda K; Maeda A; Yukawa T; Saisho S; Shimizu K; Yamaguchi Y; Oka M; Nakayama E; Lundqvist A; Kiessling R; Seliger B; Nakata M
    PLoS One; 2015; 10(10):e0139809. PubMed ID: 26439264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.
    Cho S; Lee TS; Song IH; Kim AR; Lee YJ; Kim H; Hwang H; Jeong MS; Kang SG; Hong HJ
    PLoS One; 2017; 12(2):e0170078. PubMed ID: 28166242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway.
    Wang Y; Yu H; Xie X; Deng T; Ye L; Wu L; Ding X; Yang Z; Zhu Q; Li J; Zheng Y; Yu Z; Chen G
    Oncogene; 2021 Jun; 40(25):4324-4337. PubMed ID: 34079085
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Samankul A; Senawong G; Utaiwat S; Prompipak J; Woranam K; Phaosiri C; Sripa B; Senawong T
    Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512080
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.